Greentech Media submits:
By Jeff St. John
Last year, [[IBM]] launched a consulting practice, called "Green Sigma," based on taking sensor data and analysis software and applying them toward reducing an enterprise's overall carbon footprint and energy and water use.
FP Trading Desk submits:
While Apple Inc.’s (AAPL) one million iPhone 3GS sales in its first weekend available is a remarkable achievement, it is even more impressive given that international distribution was narrower than in the past at just eight countries versus 21 previously.
These early sales results demonstrate the willingness of consumers to buy smartphones despite recessionary headwinds. It also supports expansion of the market and bodes well for Research In Motion Ltd. (RIMM) and Palm Inc. (PALM) given that the 3GS costs $199 and was launched amidst more competitive offerings when compared to the 3G launch, according to RBC Capital Markets analyst Mike Abramsky.
Eric Savitz (Barron's) submits:
Intel (INTC) and Nokia (NOK) have announced a long-term collaboration to develop a new class of mobile computing chips and devices that will include high-bandwidth mobile communications and ubiquitous Internet connectivity. The companies said they are seeking to define a new mobile platform beyond smart phones, netbooks and notebooks to new types of hardware, software and services.
The companies said the deal includes collaboration on several open source mobile Linux software projects, including the Moblin platform for Atom-based processors and the Maemo platform developed by Nokia. Intel will acquire a Nokia HSPA/3G modem IP license for use in future projects.
Research Recap submits:
Fitch Ratings says that 15% of mortgage loans by value in UK prime RMBS master trust programs are in negative equity. The agency expects that to increase to 34% if house prices fall in line with Fitch’s expectations of a 30% house price decline peak to trough, which would mean a further 14% fall from today’s values.
Of the 2.7 million prime mortgage loans totalling GBP 263 bn securitised through RMBS, more than GBP 39 bn of loans are in negative equity and this figure will rise further as house prices continue to fall.
FP Trading Desk submits:
News information provider Thomson Reuters Corp. (TRI) announced plans Monday to de-list from the NASDAQ and London Stock Exchange and integrate their dual-listed structure, but UBS sees the company's inflated value as reason for investors to sell instead of accepting the swap.
Under terms of the plan, any holders of the British PLC stock will get an equivalent number of Corp. stock. This should happen in the third quarter if shareholders approve the deal in August.
Excerpt from fund manager John Hussman's weekly essay on the U.S. market:
Excerpt from the Hussman Funds' Weekly Market Comment (6/22/09):
No question about it, the stock market has enjoyed a nice rebound from deeply oversold conditions, amounting to a recovery of just under 1/3 of losses that the market suffered from its 2007 peak. This has been accompanied, until recent weeks, by an easing in risk aversion from what, in hindsight, could be called “fear lows” (though not necessarily the “revulsion lows”) of this downturn.
Derek Lowe submits:
What's really going on with Medarex (MEDX) and ipilimumab? The company made news over the weekend with a press release from the Mayo Clinic, detailing what appears to be a substantial response in two prostate cancer patients. But the more you look at the story, the harder it is to figure out anything useful.
As this WebMD piece makes clear, this study is not a trial of ipilimumab as a single agent. The patients are undergoing prolonged androgen ablation, the testosterone-suppressing therapy that's been around for many years and is one of the standard options for prostate cancer. The trial is to see if ipilimumab has any benefit when it's added to this protocol - basically, to see if it can advance the standard of care a bit.
